Skip to main content
U.S. flag

An official website of the United States government

Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease

Bibliographic

Year of Publication:
2006
Contact PI Name:
Richard E. Hartman
Contact PI Affiliation:
Department of Psychology, Loma Linda University, Loma Linda, California, USA
Co-Authors:
Aartie Shah, Anne M. Fagan, Katherine E. Schwetye, Maia Parsadanian, Risa N. Schulman, Mary Beth Finn, David M. Holtzman
Primary Reference (PubMED ID):
Funding Source:
Stewart and Lynda Resnick Revocable Trust
Study Goal and Principal Findings:

Although there are no proven ways to delay onset or slow progression of Alzheimer's disease (AD), studies suggest that diet can affect risk. Pomegranates contain very high levels of antioxidant polyphenolic substances as compared to other fruits and vegetables. Polyphenols have been shown to be neuroprotective in different model systems. We asked whether dietary supplementation with pomegranate juice (PJ) would influence behavior and AD-like pathology in a transgenic mouse model. Transgenic mice (APPsw/Tg2576) received either PJ or sugar water control from 6 to 12.5months of age. PJ-treated mice learned water maze tasks more quickly and swam faster than controls. Mice treated with PJ had significantly less (∼50%) accumulation of soluble Aβ42 and amyloid deposition in the hippocampus as compared to control mice. These results suggest that further studies to validate and determine the mechanism of these effects, as well as whether substances in PJ may be useful in AD, should be considered.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Dietary Interventions & Supplements
Therapeutic Agent:
Pomegranate Juice
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
APP
Strain/Genetic Background:
Not Reported

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Morris Water Maze
Histopathology
Fibrillar beta Amyloid Deposits
beta Amyloid Load
Cerebral Amyloid Angiopathy (CAA)
Dystrophic Neurites
Degenerating Neurites
Biochemical
Brain-Buffer Soluble beta Amyloid Peptide 42
Brain-Buffer Insoluble beta Amyloid Peptide 40
Brain-Buffer Soluble beta Amyloid Peptide 40
APP-CTF83 (CTF alpha)
APP-CTF99 (CTF beta)
Brain-Buffer Insoluble beta Amyloid Peptide 42
Amyloid Precursor Protein (APP)
APP-CTFs